Adaptimmune (NASDAQ:ADAP) inks an agreement with Tokyo-based Noile-Immune Biotech to co-develop next-generation SPEAR T-cell products incorporating the latter's PRIME (proliferation-inducing and migration-enhancing) technology to augment CAR-T cell activity. Under the terms of the agreement, ADAP will pay Noile-Immune up to $312M across all programs plus mid-single-digit royalties on net sales. Source: Seeking Alpha 27/8/2019